



Pharmaids Pharmaceuticals Limited

Date: 13-11-2024

To
The Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of Board Meeting held on Wednesday, 13th November 2024

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation dated 07th November, 2024 regarding the Notice for the Board Meeting, the Board of Directors of the Company in their Meeting held today i.e., Wednesday, November 13, 2024, inter alia have considered and approved the following:

1. The unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the Quarter and Half year ended 30th September, 2024 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) which has been duly reviewed and recommended by the Audit Committee.

We enclose herewith the said Unaudited Financial Results along with the Limited Review Report issued by M/s PPKG & Co, Statutory Auditors of the Company.

The Financial Results are also available on the website of the Company at www.pharmaids.com and on the website of BSE www.bseindia.com.

The Board Meeting commenced at 01.45 P.M. and concluded at 02:40 P.M.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

Independent Auditor's Review Report on unaudited quarterly standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of Pharmaids Pharmaceuticals Limited for the quarter and half year ended 30th September 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.




Our conclusion is not modified in respect of this matter.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)

Giridhari Lal Toshniwal
Giridhari Lal Toshniwal
(Partner)

(M.No- 205140)

UDIN: 24205140BKA LDF1457



Place: Hyderabad

Date: 13th November 2024

PHARMAIDS PHARMACEUTICALS LIMITED

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

CIN: L52520KA1989PLC173979

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2024

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
	Sep 30, 2024	Jun 30, 2024	Sep 30, 2023	Sep 30, 2024	Sep 30, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income						
Revenue from operations	83.40	16.65	-	100.05	-	2.78
Other income	0.51	0.31	(25.77)	0.82	11.43	79.50
Total income	83.91	16.96	(25.77)	100.87	11.43	82.27
Expenses						
Cost of materials consumed	-	-	-	-	-	-
Purchase of stock-in-trade	61.50	21.70	-	83.20	-	25.42
Changes in inventories of finished goods and work-in-progress	4.10	(6.70)	-	(2.60)	-	(22.93)
Employee benefits expense	71.71	73.96	47.22	145.67	83.35	198.78
Finance costs	1.27	1.27	0.01	2.55	0.13	33.34
Depreciation and amortisation expense	4.96	4.78	0.87	9.74	1.69	17.72
Other expenses	59.00	99.40	54.86	158.40	179.49	438.62
Total expenses	202.54	194.42	102.96	396.96	264.66	690.95
Profit/ (Loss) before exceptional items and tax	(118.63)	(177.46)	(128.73)	(296.09)	(253.23)	(608.67)
Exceptional items	-	-	-	-	-	-
Prior period share of profit/interest form Associate	-	-	-	-	3.81	-
Profit/ (Loss) before tax	(118.63)	(177.46)	(128.73)	(296.09)	(249.42)	(608.67)
Tax expense						
Current tax	-	-	-	-	-	-
Deferred tax	(17.97)	(15.12)	(78.29)	(33.09)	(68.94)	(113.69)
Total Tax Expense	(17.97)	(15.12)	(78.29)	(33.09)	(68.94)	(113.69)
Profit/ (Loss) for the year	(100.66)	(162.34)	(50.44)	(263.00)	(180.48)	(494.98)
Other comprehensive income						
(i) Items that will not be reclassified subsequently to profit or loss						
Re-measurement on defined benefit plans and equity instruments	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
(ii) Items that will be reclassified subsequently to profit or loss						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
Other comprehensive income for the year, net of taxes	-	-	-	-	-	-
Total comprehensive income for the year	(100.66)	(162.34)	(50.44)	(263.00)	(180.48)	(494.98)

PHARMAIDS PHARMACEUTICALS LIMITED

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

CIN: L52520KA1989PLC173979

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2024

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
	Sep 30, 2024	Jun 30, 2024	Sep 30, 2023	Sep 30, 2024	Sep 30, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	2,144.38	3,526.78	2,144.38	3,526.78
Other Equity (excluding revaluation reserve)						3,579.31
Earnings per equity share						
Basic (in Rs)	(0.29)	(0.46)	(0.24)	(0.75)	(0.84)	(2.18)
Diluted (in Rs)	(0.29)	(0.46)	(0.23)	(0.75)	(0.81)	(2.18)

Place: Bengaluru

Date: 13-11-2024

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited****Venu Madhava Kaparthy**

Whole Time Director

DIN : 00021699

Notes to Accounts:

1. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on November 13, 2024.
2. The unaudited standalone financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in terms of regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The company operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Place: Bengaluru

Date: 13-11-2024

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited****Venu Madhava Kaparthy**

Whole Time Director

DIN : 00021699

Standalone Balance Sheet

All figures in Rs. Lacs unless otherwise specified

Particulars	As at	As at
	30 Sep 2024 (Unaudited)	31 March 2024 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,618.91	1,613.85
Capital work-in-progress	230.74	229.72
Right-of-use assets	34.62	41.32
Financial assets		
(i) Investments	5,259.88	5,259.54
(ii) Other financial assets	502.94	495.17
Deferred tax assets (net)	417.53	384.44
Total non-current assets	8,064.62	8,024.05
Current assets		
Inventories	25.53	22.93
Financial assets		
(i) Trade receivables	75.23	-
(ii) Cash and cash equivalents	84.58	245.93
Other current assets	194.71	207.16
Total current assets	380.04	476.01
TOTAL ASSETS	8,444.65	8,500.06
EQUITY AND LIABILITIES		
Equity		
Equity share capital	3,526.78	3,526.78
Other equity	3,316.31	3,579.31
Total equity	6,843.10	7,106.09
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	1,416.00	1,250.00
(ii) Lease liabilities	21.46	27.79
Provisions	5.84	5.81
Total non-current liabilities	1,443.30	1,283.60
Current liabilities		
Financial liabilities		
(i) Lease liabilities	15.44	14.71
(ii) Trade payables		
total outstanding dues of micro and small enterprises		
total outstanding dues of creditors other than micro and small enterprises	45.46	-
(iii) Other financial liabilities	83.81	76.64
Provisions	0.22	0.48
Other current liabilities	13.32	18.55
Total Current Liabilities	158.25	110.37
TOTAL EQUITY AND LIABILITIES	8,444.65	8,500.06

Place: Bengaluru
Date: 13-11-2024

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN: 00021699

Standalone Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

Particulars	Period ended	Period ended
	30 Sep 2024	30 Sep 2023
	(Unaudited)	(Unaudited)
Cash flows from operating activities		
Net Profit Before Tax	(296.09)	(249.42)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>		
Depreciation	9.74	1.69
Interest income	(0.82)	(11.08)
Finance Cost	2.55	-
Liabilities written back	-	(64.74)
Provision for bad debts	-	80.81
Share of loss in partnership firm	117.03	60.58
<i>Adjustments for changes in working capital:</i>		
(Increase)/decrease in inventories	(2.60)	-
(Increase)/decrease in trade receivables	(75.23)	124.61
(Increase)/decrease in other current assets	12.45	144.11
Increase/(decrease) in trade payables	45.46	(109.41)
Increase/(decrease) in other financial liabilities	7.17	8.76
Increase/(decrease) in other provisions	(0.23)	4.39
Increase/(decrease) in other current liabilities	(5.23)	(27.42)
Cash generated from/(used in) operations	(185.79)	(37.12)
Income tax paid	-	-
Net cash flows generated from/(used in) operating activities (A)	(185.79)	(37.12)
Cash flows from investing activities		
Purchase of property, plant and equipment incl. CWIP	(9.11)	(1,071.33)
Interest on bank deposits	0.19	11.08
Investment in subsidiaries	(33.50)	(85.00)
Loans given	(91.00)	-
Net cash flow generated from/(used in) investing activities (B)	(133.42)	(1,145.25)
Cash flow from Financing activities		
Proceeds from borrowing	166.00	-
Repayment of lease liabilities	(8.14)	-
Net cash flow generated from/(used in) financing activities (C)	157.86	-
Net increase in cash and cash equivalents (A+B+C)	(161.35)	(1,182.37)
Cash and cash equivalents at the beginning of the year	245.93	1,275.42
Cash and cash equivalents at the end of the year	84.58	93.05
Cash and cash equivalents comprise		
Cash on hand	0.65	1.06
Balances with banks in current & deposit accounts	83.93	91.99
Total cash and cash equivalents	84.58	93.05

Place: Bengaluru
Date: 13-11-2024

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN: 00021699

Independent Auditor's Review Report on unaudited quarterly consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited (Holding Company)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Pharmaids Pharmaceuticals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiaries for the quarter and half year ended 30th September 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - i. Adita Bio Sys Private Limited
 - ii. Siri Labvivo Diet Private Limited (step down subsidiary)
 - iii. Spring labs (step down subsidiary)
 - iv. Anugraha Chemicals Spring Labs
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and

5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001.

Branch Office : VIJAYAWADA

Ph : +91-40-23205049, 6613 2176, 3516 5760 | E-mail : giri@ppkg.com | www.batgach.com

Associate Office at : ● AHMEDABAD ● BANGALORE ● CHENNAI ● DELHI ● GUWAHATI ● JAIPUR ● JODHPUR ● INDORE ● KOLKATA
● MUMBAI ● PATNA ● TRIVANDRUM ● SILCHAR (ASSAM)


measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 2 subsidiaries and 2 step down subsidiaries included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs.896.95 Lakhs, total net (loss) after tax of Rs. (422.79) Lakhs and total comprehensive (loss) of Rs.(422.79)Lakhs for the quarter and half year ended 30th September 2024, respectively and cash flows (net) of Rs. (39.84) Lakhs for the period ended 30th September 2024 as considered in the consolidated unaudited financial results.

These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Consolidated Financial Statement is not modified in respect of the above matters.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)


Giridhari Lal Toshniwal
(Partner)
(M.No- 205140)
UDIN: 24205140BKALOG9974



Place: Hyderabad
Date: 13th November 2024

PHARMAIDS PHARMACEUTICALS LIMITED

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

CIN: L52520KA1989PLC173979

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2024

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
	Sep 30, 2024	Jun 30, 2024	Sep 30, 2023	Sep 30, 2024	Sep 30, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income						
Revenue from operations	523.93	473.07	-	997.00	-	1,511.21
Other income	1.32	0.94	(25.77)	2.27	11.43	87.82
Total income	525.25	474.02	(25.77)	999.27	11.43	1,599.03
Expenses						
Cost of materials consumed	236.22	276.23	-	512.45	-	1,053.10
Purchase of stock-in-trade	110.35	33.47	-	143.82	-	4.40
Changes in inventories of finished goods and work-in-progress	4.66	68.22	-	72.88	-	116.23
Employee benefits expense	287.06	299.20	47.22	586.26	83.35	919.61
Finance costs	33.46	26.13	0.01	59.58	0.13	156.83
Depreciation and amortisation expense	61.48	56.59	0.87	118.07	1.69	172.49
Other expenses	141.42	136.66	54.86	278.07	179.49	656.70
Total expenses	874.65	896.50	102.96	1,771.15	264.66	3,079.36
Profit/ (Loss) before exceptional items and tax	(349.39)	(422.48)	(128.73)	(771.88)	(253.23)	(1,480.33)
Exceptional items	(6.95)	(7.63)	-	(14.58)	-	(81.81)
Prior period share of profit/interest form Associate	-	-	-	-	3.81	-
Profit/ (Loss) before tax	(356.34)	(430.11)	(128.73)	(786.46)	(249.42)	(1,562.14)
Tax expense						
Current tax	-	-	-	-	-	-
Tax paid for earlier years	0.37	-	-	0.37	-	-
Deferred tax	(100.41)	(117.66)	(78.29)	(218.07)	(68.94)	(377.82)
Total Tax Expense	(100.03)	(117.66)	(78.29)	(217.69)	(68.94)	(377.82)
Profit/ (Loss) for the year	(256.31)	(312.45)	(50.44)	(568.76)	(180.48)	(1,184.31)
Other comprehensive income						
(i) Items that will not be reclassified subsequently to profit or loss						
Re-measurement on defined benefit plans and equity instruments	-	-	-	-	-	(46.51)
Income tax effect	-	-	-	-	-	14.51
(ii) Items that will be reclassified subsequently to profit or loss						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
Other comprehensive income for the year, net of taxes	-	-	-	-	-	(32.00)
Total comprehensive income for the year	(256.31)	(312.45)	(50.44)	(568.76)	(180.48)	(1,216.31)

PHARMAIDS PHARMACEUTICALS LIMITED

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

CIN: L52520KA1989PLC173979

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2024

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
	Sep 30, 2024	Jun 30, 2024	Sep 30, 2023	Sep 30, 2024	Sep 30, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Profit/ (Loss) attributable to:						
Equity holders of the Holding company	(222.00)	(268.44)	-	(490.44)	-	(796.80)
Non-controlling interest	(34.30)	(44.02)	-	(78.32)	-	(387.51)
Profit/ (Loss) for the year	(256.31)	(312.45)	-	(568.76)	-	(1,184.31)
Other comprehensive income attributable to:						
Equity holders of the Holding company	-	-	-	-	-	(11.96)
Non-controlling interest	-	-	-	-	-	(20.04)
Other comprehensive income for the year	-	-	-	-	-	(32.00)
Total comprehensive income attributable to:						
Equity holders of the Holding company	(222.00)	(268.44)	(50.44)	(490.44)	(180.48)	(808.75)
Non-controlling interest	(34.30)	(44.02)	-	(78.32)	-	(407.55)
Total comprehensive income for the year	(256.31)	(312.45)	(50.44)	(568.76)	(180.48)	(1,216.31)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	2,144.38	3,526.78	2,144.38	3,526.78
Other Equity (excluding revaluation reserve)						3,677.91
Earnings per equity share						
Basic (in Rs)	(0.73)	(0.76)	(0.24)	(1.61)	(0.84)	(3.56)
Diluted (in Rs)	(0.73)	(0.76)	(0.23)	(1.61)	(0.81)	(3.56)

Place: Bengaluru

Date: 13-11-2024

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
 Whole Time Director
 DIN : 00021699

Notes to Accounts:

1. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on November 13, 2024.
2. The unaudited consolidated financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in terms of regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The group operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Place: Bengaluru
Date: 13-11-2024

**By the order of the Board of Directors
For Pharmads Pharmaceuticals Limited**

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

Consolidated Balance Sheet

All figures in Rs. Lacs unless otherwise specified

Particulars	As at	As at
	30 Sep 2024 (Unaudited)	31 March 2024 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	3,314.49	2,834.03
Capital work-in-progress	333.21	700.10
Right-of-use assets	399.33	311.73
Other Intangible Assets	54.51	54.51
Goodwill on Business purchase and consolidation	3,141.66	3,141.66
Financial assets		
(i) Other financial assets	63.53	58.01
Deferred tax assets (net)	884.85	666.79
Other non-current assets	13.50	14.04
Total non-current assets	8,205.09	7,780.87
Current assets		
Inventories	237.10	359.14
Financial assets		
(i) Trade receivables	325.52	267.87
(ii) Cash and cash equivalents	279.20	480.40
Other current assets	413.54	245.79
Total current assets	1,255.35	1,353.20
TOTAL ASSETS	9,460.45	9,134.07
EQUITY AND LIABILITIES		
Equity		
Equity share capital	3,526.78	3,526.78
Other equity	3,188.65	3,677.91
Equity attributable to the owners of the Company	6,715.43	7,204.69
Non-controlling Interest	(233.35)	(155.03)
Total equity	6,482.08	7,049.67
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	598.31	358.54
(ii) Lease liabilities	319.88	246.75
(iii) Other financial liabilities	260.00	260.00
Provisions	65.72	61.54
Total non-current liabilities	1,243.91	926.83
Current liabilities		
Financial liabilities		
(i) Borrowings	438.60	176.70
(ii) Lease liabilities	88.86	71.29
(iii) Trade payables		
total outstanding dues of micro and small enterprises	217.95	405.41
total outstanding dues of creditors other than micro and small enterpr	371.68	106.42
(iv) Other financial liabilities	546.25	339.94
Provisions	0.22	7.61
Other current liabilities	70.89	50.21
Total Current Liabilities	1,734.46	1,157.58
TOTAL EQUITY AND LIABILITIES	9,460.45	9,134.07

Place: Bengaluru
Date: 13-11-2024

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN: 00021699

Consolidated Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

Particulars	Period ended	Period ended
	30 Sep 2024	30 Sep 2023
	(Unaudited)	(Unaudited)
Cash flows from operating activities		
Net Profit Before Tax	(786.46)	(249.42)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>		
Depreciation	118.07	1.69
Interest income	(1.95)	(11.08)
Finance Cost	59.58	-
Liabilities written back	-	(64.74)
(Gain)/ Loss on sale of fixed asset	14.58	-
Provision for bad debts	-	80.81
<i>Adjustments for changes in working capital:</i>		
(Increase)/decrease in inventories	122.93	-
(Increase)/decrease in trade receivables	(51.54)	124.61
(Increase)/decrease in other current assets	(21.78)	144.11
Increase/(decrease) in trade payables	71.69	(109.41)
Increase/(decrease) in other financial liabilities	75.98	8.76
Increase/(decrease) in other provisions	(3.21)	4.39
Increase/(decrease) in other current liabilities	259.64	(27.42)
Cash generated from/(used in) operations	(142.47)	(37.12)
Income tax paid	(0.37)	-
Net cash flows generated from/(used in) operating activities (A)	(142.84)	(37.12)
Cash flows from investing activities		
Purchase of property, plant and equipment incl. CWIP	(237.75)	(1,071.33)
Sale of property, plant and equipment	16.25	-
Interest on bank deposits	0.20	11.08
Investment in subsidiaries	-	(85.00)
Loans given	(25.00)	-
Net cash flow generated from/(used in) investing activities (B)	(246.30)	(1,145.25)
Cash flow from Financing activities		
Proceeds from borrowing	264.77	-
Interest on loan	(40.46)	-
Repayment of lease liabilities	(36.37)	-
Net cash flow generated from/(used in) financing activities (C)	187.95	-
Net increase in cash and cash equivalents (A+B+C)	(201.20)	(1,182.37)
Cash and cash equivalents at the beginning of the year	480.40	1,275.42
Cash and cash equivalents at the end of the year	279.20	93.05
Cash and cash equivalents comprise		
Cash on hand	1.64	1.06
Balances with banks in current & deposit accounts	150.82	91.99
Deposits with original maturity of less than 3 months	126.74	-
Total cash and cash equivalents	279.20	93.05

Place: Bengaluru

Date: 13-11-2024

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**

Venu Madhava Kaparthy

Whole Time Director

DIN: 00021699